In recent months core activities of EMAV included the close consultation of EMAV in particular with the European Commission in the changed process and timeline for the implementation of the Reg. (EU) 2019/6 and for the publication of a GMP standard for autogenous vaccines, the work on new EMAV projects, like for rationales for the EMAV GMP proposal, for a new EMAV ROADMAP and for epidemiological issues and the admission of new EMAV members, Dr. Klaus-Peter Behr, Chairman of the association, reported at the annual meeting in May in Berlin.
In order to adequately address the growing and continuously changing challenges related to improving animal health, producing healthy food, and ensuring animal welfare in the future, principles of an EMAV ROADMAP 2025-2028 were thoroughly discussed at an EMAV workshop in Berlin. This ROADMAP will support the identification of key targets for EMAV for the moment of the publication and implementation of the Implementing Act and uniform rules on good manufacturing practice for inactivated autogenous veterinary vaccines and the time period after implementation of Reg. (EU) 2019/6 for autogenous vaccines.
Based on an initiative of the board, ideas “thinking out of the box”, new inspirations and suggestions submitted by the members in recent months were evaluated in a working group headed by Maarten de Gussem, Deputy Chair of EMAV. EMAV members agreed that the new ROADMAP will include a longer-term strategy and short-term tactics and will be inspired by the joint EU medicines agencies’ network strategy to 2028 (EMANS) too. Therefore the strategy is focusing on accessibility, availability and on benefits of using AV, like for the reduction in the use of Antibiotics, for Animal Welfare and Sustainability.
The work on and with the EMAV ROADMAP is being continuously pursued and will also be a topic at the Association's meetings in April of the coming year in Bologna/Italy, Gerfried Zeller, Managing Director of EMAV, announced.